Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with ^sup 68^Ga-DOTA-peptides, correla...
Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with ^sup 68^Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy
About this item
Full title
Author / Creator
Publisher
Heidelberg: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Heidelberg: Springer Nature B.V
More information
Scope and Contents
Contents
Background High-grade gliomas (HGGs) express somatostatin receptors (SSTR), rendering them candidates for peptide receptor radionuclide therapy (PRRT). Our purpose was to evaluate the potential of ^sup 68^Ga-DOTA-1-Nal^sup 3^-octreotide (^sup 68^Ga-DOTANOC) or ^sup 68^Ga-DOTA-Tyr^sup 3^-octreotide (^sup 68^Ga-DOTATOC) to target SSTR subtype 2 (SSTR...
Alternative Titles
Full title
Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with ^sup 68^Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1732876117
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1732876117
Other Identifiers
E-ISSN
2191-219X
DOI
10.1186/s13550-015-0106-2
